IMS reported Impact Therapeutics in its R&D FOCUS drug news
IMSDRUGNEWS has a two-page introduction of IMPACT Therapeutics and IMPACT’s three ongoing oncology programs, in the Dec.19th, 2011(Volume 20, No.51) issue of R&D FOCUS drugnews.
Founded in 2009, IMPACT Therapeutics, Inc. (IMPACT) is dedicated to the discovery, development and commercialization of novel and “best-in-class” therapeutics to treat cancer and other life-threatening diseases. Since its inception, IMPACT has successfully built a new and effective scientific and business model and made tremendous progress in three oncology drug discovery areas: Microtubule Inhibitors, PARP-1 Inhibitors, and Hedgehog Pathway Inhibitors.
The (IMS R&D FOCUS drug news) is a weekly publication from IMS LifeCycle. It includes reports on new drug launches, approvals, licensing, and company focus.
IMSDRUGNEWS is especially useful to evaluate new research developments on drugs and pharmaceuticals, and to locate the latest news concerning research and development trends and ideas.